Yüklüyor......
Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
OBJECTIVE: Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who had failed prior chemotherapy. Subsequent phase III trials in previously untreated patients have failed to demonstrat...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Medknow Publications
2010
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2930654/ https://ncbi.nlm.nih.gov/pubmed/20835310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1817-1737.65047 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|